Mucormycosis pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
* Neutrophils play a major part in destroying fungal hyphae, once spores germinate. Macrophages and monocytes may also play part in host defense mechanisms against fungi causing mucormycosis (specifically alveolar macrophages prevent germination of spores).<ref name="pmid2490078">{{cite journal |vauthors=Waldorf AR |title=Pulmonary defense mechanisms against opportunistic fungal pathogens |journal=Immunol. Ser. |volume=47 |issue= |pages=243–71 |year=1989 |pmid=2490078 |doi= |url=}}</ref> Consequently, mucormycosis develops exclusively in immunocompromised patients who lack these defense mechanisms. Hyperglycemia, acidosis and corticosteroid treatment have also been known to hinder immunity (specifically the actions of phagocytic cells), which also puts patients with diabetes and DKA at an increased risk of acquiring mucormycosis.<ref name="pmid16020690">{{cite journal |vauthors=Spellberg B, Edwards J, Ibrahim A |title=Novel perspectives on mucormycosis: pathophysiology, presentation, and management |journal=Clin. Microbiol. Rev. |volume=18 |issue=3 |pages=556–69 |year=2005 |pmid=16020690 |pmc=1195964 |doi=10.1128/CMR.18.3.556-569.2005 |url=}}</ref> | * Neutrophils play a major part in destroying fungal hyphae, once spores germinate. Macrophages and monocytes may also play part in host defense mechanisms against fungi causing mucormycosis (specifically alveolar macrophages prevent germination of spores).<ref name="pmid2490078">{{cite journal |vauthors=Waldorf AR |title=Pulmonary defense mechanisms against opportunistic fungal pathogens |journal=Immunol. Ser. |volume=47 |issue= |pages=243–71 |year=1989 |pmid=2490078 |doi= |url=}}</ref> Consequently, mucormycosis develops exclusively in immunocompromised patients who lack these defense mechanisms. Hyperglycemia, acidosis and corticosteroid treatment have also been known to hinder immunity (specifically the actions of phagocytic cells), which also puts patients with diabetes and DKA at an increased risk of acquiring mucormycosis.<ref name="pmid16020690">{{cite journal |vauthors=Spellberg B, Edwards J, Ibrahim A |title=Novel perspectives on mucormycosis: pathophysiology, presentation, and management |journal=Clin. Microbiol. Rev. |volume=18 |issue=3 |pages=556–69 |year=2005 |pmid=16020690 |pmc=1195964 |doi=10.1128/CMR.18.3.556-569.2005 |url=}}</ref> | ||
* In order to cause disease, the agents of mucormycosis must acquire from the host sufficient iron for growth, must evade host phagocytic defense mechanisms, and must access vasculature to disseminate. | * In order to cause disease, the agents of mucormycosis must acquire from the host sufficient iron for growth, must evade host phagocytic defense mechanisms, and must access vasculature to disseminate. | ||
* In immounocompromised hosts (including diabetics), iron is released from sequestering proteins making it available to fungi for growth within the body.<ref name="pmid6816646">{{cite journal |vauthors=Artis WM, Fountain JA, Delcher HK, Jones HE |title=A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability |journal=Diabetes |volume=31 |issue=12 |pages=1109–14 |year=1982 |pmid=6816646 |doi= |url=}}</ref> This process alongwith a reduced number of neutrophils and phagocytes leads to fungal proliferation.<ref name="pmid8486769">{{cite journal |vauthors=Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, Van Landuyt HW, Schneider YJ |title=Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies |journal=J. Clin. Invest. |volume=91 |issue=5 |pages=1979–86 |year=1993 |pmid=8486769 |pmc=288195 |doi=10.1172/JCI116419 |url=}}</ref> Damage to the endothelial cells by fungi causing mucormycosis leads to vascular invasion, subsequent dissemination and tissue necrosis. | * In immounocompromised hosts (including diabetics), iron is released from sequestering proteins making it available to fungi for growth within the body.<ref name="pmid6816646">{{cite journal |vauthors=Artis WM, Fountain JA, Delcher HK, Jones HE |title=A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability |journal=Diabetes |volume=31 |issue=12 |pages=1109–14 |year=1982 |pmid=6816646 |doi= |url=}}</ref> This process alongwith a reduced number of neutrophils and phagocytes leads to fungal proliferation.<ref name="pmid8486769">{{cite journal |vauthors=Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, Van Landuyt HW, Schneider YJ |title=Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies |journal=J. Clin. Invest. |volume=91 |issue=5 |pages=1979–86 |year=1993 |pmid=8486769 |pmc=288195 |doi=10.1172/JCI116419 |url=}}</ref> Damage to the endothelial cells by fungi causing mucormycosis leads to vascular invasion, subsequent dissemination and tissue necrosis. R. oryzae spores but not germlings (i.e., pregerminated spores) have the ability to attach themselves to subendothelial matrix proteins including laminin and type IV collagen.<ref name="pmid8738422">{{cite journal |vauthors=Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D |title=Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components |journal=Eur. J. Cell Biol. |volume=70 |issue=1 |pages=76–83 |year=1996 |pmid=8738422 |doi= |url=}}</ref> <ref name="pmid15664916">{{cite journal |vauthors=Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE |title=Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro |journal=Infect. Immun. |volume=73 |issue=2 |pages=778–83 |year=2005 |pmid=15664916 |pmc=547117 |doi=10.1128/IAI.73.2.778-783.2005 |url=}}</ref> | ||
Revision as of 15:45, 24 May 2017
|
Mucormycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
Pathophysiology
- Fungi of the order Mucorales (class Zygomycetes) are causes of mucormycosis, a life-threatening fungal infection affecting immunocompromised hosts in either developing or industrialized countries.
- Species belonging to the family Mucoraceae are isolated more frequently from patients with mucormycosis.
- Among the Mucoraceae, Rhizopus oryzae (Rhizopus arrhizus) is by far the most common cause of infection. Increasing cases of mucormycosis have been also reported due to infection with Cunninghamella spp.
- Neutrophils play a major part in destroying fungal hyphae, once spores germinate. Macrophages and monocytes may also play part in host defense mechanisms against fungi causing mucormycosis (specifically alveolar macrophages prevent germination of spores).[1] Consequently, mucormycosis develops exclusively in immunocompromised patients who lack these defense mechanisms. Hyperglycemia, acidosis and corticosteroid treatment have also been known to hinder immunity (specifically the actions of phagocytic cells), which also puts patients with diabetes and DKA at an increased risk of acquiring mucormycosis.[2]
- In order to cause disease, the agents of mucormycosis must acquire from the host sufficient iron for growth, must evade host phagocytic defense mechanisms, and must access vasculature to disseminate.
- In immounocompromised hosts (including diabetics), iron is released from sequestering proteins making it available to fungi for growth within the body.[3] This process alongwith a reduced number of neutrophils and phagocytes leads to fungal proliferation.[4] Damage to the endothelial cells by fungi causing mucormycosis leads to vascular invasion, subsequent dissemination and tissue necrosis. R. oryzae spores but not germlings (i.e., pregerminated spores) have the ability to attach themselves to subendothelial matrix proteins including laminin and type IV collagen.[5] [6]
References
- ↑ Waldorf AR (1989). "Pulmonary defense mechanisms against opportunistic fungal pathogens". Immunol. Ser. 47: 243–71. PMID 2490078.
- ↑ Spellberg B, Edwards J, Ibrahim A (2005). "Novel perspectives on mucormycosis: pathophysiology, presentation, and management". Clin. Microbiol. Rev. 18 (3): 556–69. doi:10.1128/CMR.18.3.556-569.2005. PMC 1195964. PMID 16020690.
- ↑ Artis WM, Fountain JA, Delcher HK, Jones HE (1982). "A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability". Diabetes. 31 (12): 1109–14. PMID 6816646.
- ↑ Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, Van Landuyt HW, Schneider YJ (1993). "Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies". J. Clin. Invest. 91 (5): 1979–86. doi:10.1172/JCI116419. PMC 288195. PMID 8486769.
- ↑ Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D (1996). "Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components". Eur. J. Cell Biol. 70 (1): 76–83. PMID 8738422.
- ↑ Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE (2005). "Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro". Infect. Immun. 73 (2): 778–83. doi:10.1128/IAI.73.2.778-783.2005. PMC 547117. PMID 15664916.